Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of MERIT-1 with macitentan in inoperable chronic thromboembolic pulmonary hypertension
2013-003457-25Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of macitentan in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Long-term safety and tolerability of macitentan 10 mg. Started Apr 2014; status: completed.
02
Drugs
macitentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on 2013-003457-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003457-25.